🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are excited to spotlight transformative work from Li Tang in 𝐂𝐞𝐥𝐥 𝐒𝐭𝐞𝐦 𝐂𝐞𝐥𝐥! Unveiling 𝐈𝐋-𝟏𝟎's role in CAR-T against solid tumors—redefining cytokine's role, enhancing therapy efficacy. #Immunotherapy #CARTCells cell.com/cell-stem-cell…

PD-1 and its ligands dimerize in cis via transmembrane domain interactions to enhance T cell inhibition Jun Wang Science Immunology Michael Dustin science.org/doi/10.1126/sc…

Just shared insights on the PEAK Theory of CAR-T tonic signal in our latest commentary! This theory not only sharpens our understanding of metabolic processes in #CARTCells but also guides the optimization of CAR-T therapies. #CellTherapy #Immunotherap nature.com/articles/s4225…

Happy to share our 1st TCR-T therapy study with Dr. Chenqi Xu, published in Cell Chemical Biology: Transient Hydroxycholesterol Treatment Promotes Long-term TCR-T Efficacy! cell.com/cell-chemical-… #Immunotherapy #TCRTCells #CancerResearch #CARTCells #TCellTherapy #Innovation

Excited to share our Research Highlight for a recent study published in NEJM! The "Hangzhou Protocol" is a major leap in treating T-cell leukemia! 🚀No chemo or immunosuppressants are needed! link.springer.com/article/10.103… #Hematology #CancerTreatment #CAR_T #NEJM

Important perspective in Nature Rev Immunol on the Basic-Rich Sequence (BRS) signaling motif from Dr. Chenqi Xu's Lab! Fascinating to see how this charge-based motif in immunoreceptors and membrane proteins plays such a broad role in immune response regulation.

🔬 Thrilled to share our new paper in Immunity with Chenqi Xu ! Novel Phase-CAR that promotes phase separation forms mature immunological synapses & shows enhanced anti-tumor activity. #CARTcell cell.com/immunity/fullt…

Glad to share our new publication Immunity , reporting a new E-CAR that can form mature immunological synapse through phase separation. Paper link: authors.elsevier.com/a/1kATc_OR%7Ey…

Thrilled to share our Science Immunology paper! Rodent PD-1 is weaker than human PD-1 (reduced ligand binding & signaling) & lacks a conserved vertebrate motif. Humanizing mouse PD-1 disrupts T cell anti-tumor responses, raising many questions. Kudos to Takeya Masubuchi for leading

Now online! Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs dlvr.it/TJZsP5

D-STAR: The Gemini Guardians redefining dual-targeting of immune cell ... sciencedirect.com/science/articl…

Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function. Haopeng Wang found ubiquitination of LAG3 promotes its inhibitory function rather than its degradation, and is required for suppression of antitumor immunity in vivo. ow.ly/xOKh50VkhNt

Just published a review on CAR-T tonic signaling and introduced the "Peak Theory"—finding the optimal signaling level to overcome T-cell exhaustion and enhance efficacy in cancer, autoimmune diseases, and more. link.springer.com/article/10.100… #Immunotherapy #CART

Science Spotlight: New insight into LAG3's checkpoint function, a blood-based T cell assay for Type I diabetes, a degrader using a new E3 ligase, and paper from newcos. BioCentury's roundup of translational innovations buff.ly/RYy1W0J

Just out in Cell! Prof. Kai W. Wucherpfennig previews our study: “Unlocking LAG3: Ubiquitin’s Unexpected Role.” LAG3's non-degradative poly-Ub by Cbl ligases flips this checkpoint ON and marks TILs that respond to PD-1/LAG3 combo therapy. cell.com/cell/fulltext/…

Understanding LAG3 immune checkpoint function nature.com/articles/d4157…

In the latest issue! Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs dlvr.it/TKZSzG

Congrats to Xinyao and Xie Chen! In eukaryotes, multiple transcription factors bind cooperatively to a regulatory region on genomic DNA to control gene expression. In this paper (bit.ly/3GV1BoP), we present an experimental metric for quantifying such cooperativity.

What a beautiful study from Dr. Bernard Malissen! A CARMIL2 gain-of-function mutation suffices to trigger most CD28 costimulatory functions in vivo rupress.org/jem/article/22…